Cycloserine 250mg capsules

Држава: Велика Британија

Језик: Енглески

Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активни састојак:

Cycloserine

Доступно од:

Neon Healthcare Ltd

АТЦ код:

J04AB01

INN (Међународно име):

Cycloserine

Дозирање:

250mg

Фармацеутски облик:

Oral capsule

Пут администрације:

Oral

Класа:

No Controlled Drug Status

Тип рецептора:

Valid as a prescribable product

Резиме производа:

BNF: 05010900; GTIN: 5033003002257

Карактеристике производа

OBJECT 1
CYCLOSERINE
Summary of Product Characteristics Updated 07-Feb-2018 | King
Pharmaceuticals Ltd
1. Name of the medicinal product
CYCLOSERINE
2. Qualitative and quantitative composition
Each capsule contains as active ingredient 250 mg of cycloserine.
3. Pharmaceutical form
Capsule, hard.
4. Clinical particulars
4.1 Therapeutic indications
_Actions:_ Cycloserine inhibits cell wall synthesis in susceptible
strains of Gram-positive and Gram-
negative bacteria and in Mycobacterium tuberculosis.
_Indications:_ Cycloserine is indicated in the treatment of active
pulmonary and extra-pulmonary
tuberculosis (including renal disease) when the organisms are
susceptible to this drug and after failure of
adequate treatment with the primary medications (streptomycin,
isoniazid, rifampicin and ethambutol).
Like all anti-tuberculous drugs, cycloserine should be administered in
conjunction with other effective
chemotherapy and not as the sole therapeutic agent.
Cycloserine may be effective in the treatment of acute urinary tract
infections caused by susceptible
strains of Gram-positive and Gram-negative bacteria, especially
Klebsiella/Enterobacter species and
Escherichia coli. It is generally no more and may be less effective
than other antimicrobial agents in the
treatment of urinary tract infections caused by bacteria other than
mycobacteria. Use of cycloserine in
these infections should be considered only when the more conventional
therapy has failed and when the
organism has been demonstrated to be sensitive to the drug.
4.2 Posology and method of administration
Posology
_Adults: _the usual dosage is 500 mg to 1 g daily in divided doses,
monitored by blood level determinations.
The initial adult dosage most frequently given is 250 mg twice daily
at 12-hour intervals for the first two
weeks. A daily dosage of 1g should not be exceeded.
_The elderly: _as for adults but reduce dosage if renal function is
impaired.
_Paediatric population _
The usual starting dose is 10 mg/ kg/ day, then adjusted according to
blood levels o